IMCR Immunocore Holdings plc
Price (delayed)
$29.43
Market cap
$1.47B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$1.45B
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of
Highlights
The gross profit has increased by 24% year-on-year and by 4.7% since the previous quarter
The revenue is up by 24% year-on-year and by 4.7% since the previous quarter
The EPS has grown by 10% year-on-year but it has declined by 7% since the previous quarter
IMCR's net income is down by 9% QoQ but it is up by 8% YoY
The equity has declined by 4.5% since the previous quarter and by 2.2% year-on-year
Key stats
What are the main financial stats of IMCR
Market
Valuations
Earnings
Shares outstanding
50.07M
Market cap
$1.47B
Enterprise value
$1.45B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.08
Price to sales (P/S)
4.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
Revenue
$310.2M
Gross profit
$307.47M
Operating income
-$70.46M
Net income
-$51.09M
EBIT
-$34.09M
EBITDA
-$27.98M
Free cash flow
$20.93M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
$0.42
Book value per share
$7.21
Revenue per share
$6.21
TBVPS
$20.19
Total assets
$1.01B
Total liabilities
$648.79M
Debt
$432.72M
Equity
$360.72M
Working capital
$717.68M
Debt to equity
1.2
Current ratio
4.38
Quick ratio
4.16
Net debt/EBITDA
0.82
Margins
Efficiency
Dividend
EBITDA margin
-9%
Gross margin
99.1%
Net margin
-16.5%
Operating margin
-22.7%
Return on assets
-5%
Return on equity
-14%
Return on invested capital
-4.8%
Return on capital employed
-4.3%
Return on sales
-11%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMCR stock price
How has the Immunocore Holdings stock price performed over time
Intraday
2.79%
1 week
-0.14%
1 month
0.2%
1 year
-53.64%
YTD
-0.24%
QTD
-0.81%
Financial performance
How have Immunocore Holdings's revenue and profit performed over time
Revenue
$310.2M
Gross profit
$307.47M
Operating income
-$70.46M
Net income
-$51.09M
Gross margin
99.1%
Net margin
-16.5%
The net margin has grown by 26% YoY but it has contracted by 3.8% from the previous quarter
The gross profit has increased by 24% year-on-year and by 4.7% since the previous quarter
The revenue is up by 24% year-on-year and by 4.7% since the previous quarter
IMCR's operating income is down by 18% year-on-year and by 3.5% since the previous quarter
Growth
What is Immunocore Holdings's growth rate over time
Valuation
What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
4.08
P/S
4.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.68
The EPS has grown by 10% year-on-year but it has declined by 7% since the previous quarter
IMCR's price to book (P/B) is 40% less than its 5-year quarterly average of 6.6 and 28% less than its last 4 quarters average of 5.5
The equity has declined by 4.5% since the previous quarter and by 2.2% year-on-year
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 20.6 and 35% less than its last 4 quarters average of 7.1
The revenue is up by 24% year-on-year and by 4.7% since the previous quarter
Efficiency
How efficient is Immunocore Holdings business performance
The ROIC has soared by 92% YoY and by 37% QoQ
The return on sales has surged by 51% year-on-year and by 20% since the previous quarter
The return on assets has increased by 49% year-on-year
The ROE is up by 10% year-on-year but it is down by 9% since the previous quarter
Dividends
What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMCR.
Financial health
How did Immunocore Holdings financials performed over time
The total assets is 56% greater than the total liabilities
The total liabilities has soared by 184% YoY but it fell by 8% QoQ
The total assets has surged by 69% year-on-year but it has declined by 7% since the previous quarter
The debt is 20% more than the equity
The debt has contracted by 10% from the previous quarter
The debt to equity is down by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.